Lung diseases are the leading cause of mortality worldwide. The currently available
therapies are not sufficient, leading to the urgent need for new therapies with sustained anti …

The novel coronavirus disease 2019 (COVID-19) pandemic has imposed significant public
health problems for the human populations worldwide after the 1918 influenza A virus …

Small interfering RNA (siRNA) has a huge potential for the treatment or prevention of various
lung diseases. Once the RNA molecules have successfully entered the target cells, they …

Acute viral respiratory tract infections (AVRIs) are a major burden on human health and
global economy and amongst the top five causes of death worldwide resulting in an …

Although the classical antibiotic spectinomycin is a potent bacterial protein synthesis
inhibitor, poor antimycobacterial activity limits its clinical application for treating tuberculosis …

An overview of the application of natural and synthetic, non-viral vectors for oligonucleotide
delivery into the lung is presented in this review, with a special focus on lung cancer. Due to …

XCL1, a C class chemokine also known as lymphotactin, is produced by T, NK, and NKT
cells during infectious and inflammatory responses, whereas XCR1, the receptor of XCL1, is …

The lungs have received attention as a portal for drug delivery in tuberculosis (TB) from
researchers addressing diverse objectives. These include:(a) targeting alveolar …

In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …

MicroRNAs (miRNAs) are single-stranded RNAs of 17–24 nt. These molecules regulate
gene expression at the post-transcriptional level and are differentially expressed in viral …